In a clinical trial of melanoma patients with anti-CTLA-4 antibody blockade vaccine with autologous tumor cells engineered to express GM-CSF, it was shown that patients with high level of anti-MICA autoantibody presented better response to therapy (84). Here, MICA is linked to neoplasm.